{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:10:19Z","timestamp":1787987419277,"version":"build-2784847793"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Hypomagnesemia is a known side effect of several antineoplastic agents, but its impact on outcomes of patients with cancer is not well understood. We examined whether magnesium abnormalities affect survival in patients with ovarian cancer who receive chemotherapy containing carboplatin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>We included patients with advanced ovarian cancer who had undergone surgery and chemotherapy between January 1, 2004, and December 31, 2014, at our institution. Inclusion criteria were age 18 years or older, pathology of high-grade serous carcinoma, first treatment (surgery or chemotherapy) within 60 days of diagnosis, and chemotherapy containing carboplatin. The final cohort consisted of 229 patients. Vital signs and laboratory tests were recorded at baseline and during the treatment course. The associations between magnesium abnormalities (and other clinical characteristics) and survival were analyzed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The median patient age was 64 years. Higher baseline heart rate (beats per minute; hazard ratio [HR] = 1.02, p = .002) and greater frequency of hypomagnesemia during the treatment course (HR = 1.05, p = .002) were significantly associated with shorter survival independent of completeness of tumor reduction (HR = 1.60, p = .02), and International Federation of Gynecology and Obstetrics stage (HR = 1.63, p = .01).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Baseline heart rate and the frequency of hypomagnesemia episodes during treatment are prognostic of survival for patients with advanced ovarian cancer receiving carboplatin-containing chemotherapy and tumor reductive surgery. Future research is needed for strategies to detect and prevent hypomagnesemia in this patient population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0465","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T18:05:29Z","timestamp":1554228329000},"page":"e312-e317","source":"Crossref","is-referenced-by-count":30,"title":["Hypomagnesemia and Survival in Patients with Ovarian Cancer Who Received Chemotherapy with Carboplatin"],"prefix":"10.1093","volume":"24","author":[{"given":"Wenli","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiham","family":"Qdaisat","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela T.","family":"Soliman","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois","family":"Ramondetta","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Lopez","sequence":"additional","affiliation":[{"name":"Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhosshi","family":"Narayanan","sequence":"additional","affiliation":[{"name":"Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouhao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Bruera","sequence":"additional","affiliation":[{"name":"Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Ching J.","family":"Yeung","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,2]]},"reference":[{"key":"2021122507121685700_R1","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.clon.2006.06.011","article-title":"Magnesium depletion in patients receiving cisplatin-based chemotherapy","volume":"18","author":"Hodgkinson","year":"2006","journal-title":"Clin Oncol"},{"key":"2021122507121685700_R2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/ctrv.1999.0097","article-title":"Cisplatin and hypomagnesemia","volume":"25","author":"Lajer","year":"1999","journal-title":"Cancer Treat Rev"},{"key":"2021122507121685700_R3","doi-asserted-by":"crossref","DOI":"10.3390\/nu9030296","article-title":"Serum magnesium concentrations in the Canadian population and associations with diabetes, glycemic regulation, and insulin resistance","volume":"9","author":"Bertinato","year":"2017","journal-title":"Nutrients"},{"key":"2021122507121685700_R4","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1751-7176.2011.00538.x","article-title":"The role of magnesium in hypertension and cardiovascular disease","volume":"13","author":"Houston","year":"2011","journal-title":"J Clin Hypertens"},{"key":"2021122507121685700_R5","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2337\/dc12-0226","article-title":"Hypomagnesemia in type 2 diabetic nephropathy: A novel predictor of end-stage renal disease","volume":"35","author":"Sakaguchi","year":"2012","journal-title":"Diabet Care"},{"key":"2021122507121685700_R6","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/annonc\/mds577","article-title":"Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG\/AGITG CO.17","volume":"24","author":"Vickers","year":"2013","journal-title":"Ann Oncol"},{"key":"2021122507121685700_R7","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1158\/1078-0432.CCR-08-0077","article-title":"Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome","volume":"14","author":"Vincenzi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122507121685700_R8","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/s41598-018-19835-8","article-title":"Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: A systematic review and meta-analysis","volume":"8","author":"Hsieh","year":"2018","journal-title":"Sci Rep"},{"key":"2021122507121685700_R9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chron Dis"},{"key":"2021122507121685700_R10","author":"National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE)","year":"2010"},{"key":"2021122507121685700_R11","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/annonc\/mdq550","article-title":"Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients","volume":"22","author":"Vincenzi","year":"2011","journal-title":"Ann Oncol"},{"key":"2021122507121685700_R12","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1172\/JCI33004","article-title":"When EGF is offside, magnesium is wasted","volume":"117","author":"Muallem","year":"2007","journal-title":"J Clin Invest"},{"key":"2021122507121685700_R13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(07)70108-0","article-title":"Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: A prospective study","volume":"8","author":"Tejpar","year":"2007","journal-title":"Lancet Oncol"},{"key":"2021122507121685700_R14","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00280-005-1010-7","article-title":"Magnesium depletion enhances cisplatin-induced nephrotoxicity","volume":"56","author":"Lajer","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122507121685700_R15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejphar.2017.05.034","article-title":"Magnesium attenuates cisplatin-induced nephrotoxicity by regulating the expression of renal transporters","volume":"811","author":"Saito","year":"2017","journal-title":"Eur J Pharmac"},{"key":"2021122507121685700_R16","doi-asserted-by":"crossref","first-page":"F339","DOI":"10.1152\/ajprenal.00688.2016","article-title":"Magnesium improves cisplatin-mediated tumor killing while protecting against cisplatin-induced nephrotoxicity","volume":"313","author":"Kumar","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"2021122507121685700_R17","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/j.clcc.2016.02.011","article-title":"Management of epidermal growth factor receptor inhibitor-induced hypomagnesemia: A systematic review","volume":"15","author":"Jiang","year":"2016","journal-title":"Clin Colorect Cancer"},{"key":"2021122507121685700_R18","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/0002-8703(87)90666-1","article-title":"Heart rate and cardiovascular mortality: The Framingham study","volume":"113","author":"Kannel","year":"1987","journal-title":"Am Heart J"},{"key":"2021122507121685700_R19","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ijcard.2015.01.027","article-title":"Elevated heart rate at 24\u201336h after admission and in-hospital mortality in acute in non-arrhythmic heart failure","volume":"182","author":"Lancellotti","year":"2015","journal-title":"Int J Cardiol"},{"key":"2021122507121685700_R20","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","article-title":"Heart rate as a risk factor in chronic heart failure (SHIFT): The association between heart rate and outcomes in a randomised placebo-controlled trial","volume":"376","author":"B\u00f6hm","year":"2010","journal-title":"Lancet"},{"key":"2021122507121685700_R21","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.ahj.2009.12.029","article-title":"Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women","volume":"159","author":"Cooney","year":"2010","journal-title":"Am Heart J"},{"key":"2021122507121685700_R22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijcard.2009.09.543","article-title":"The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors","volume":"141","author":"Thayer","year":"2010","journal-title":"Int J Cardiol"},{"key":"2021122507121685700_R23","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/ecc.12066","article-title":"Heart rate variability as a measure of autonomic dysfunction in men with advanced cancer","volume":"22","author":"Guo","year":"2013","journal-title":"Eur J Cancer Care"},{"key":"2021122507121685700_R24","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/ije\/dym031","article-title":"Effects of passive smoking on heart rate variability, heart rate and blood pressure: An observational study","volume":"36","author":"Felber Dietrich","year":"2007","journal-title":"Int J Epidemiol"},{"key":"2021122507121685700_R25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/PSY.0b013e318160686a","article-title":"Associations of psychosocial factors with heart rate and its short-term variability: Multi-ethnic study of atherosclerosis","volume":"70","author":"Ohira","year":"2008","journal-title":"Psychosomat Med"},{"key":"2021122507121685700_R26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3945\/an.115.008631","article-title":"Essential nutrient interactions: Does low or suboptimal magnesium status interact with vitamin d and\/or calcium status?","volume":"7","author":"Rosanoff","year":"2016","journal-title":"Adv Nutr"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0465","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0465","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/6\/e312\/41918495\/oncolo_24_6_e312.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/6\/e312\/41918495\/oncolo_24_6_e312.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T07:12:56Z","timestamp":1640416376000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/6\/e312\/6439264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,2]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,4,2]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0465","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6,1]]},"published":{"date-parts":[[2019,4,2]]}}}